Swati Tole Selected Research

etrolizumab

1/2022	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
1/2022	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
1/2022	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
1/2022	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
1/2021	An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers.
1/2021	Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.
1/2020	Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Swati Tole Research Topics

Disease

6	Ulcerative Colitis 01/2022 - 01/2020
4	Hemorrhage 01/2022 - 01/2022
3	Crohn Disease (Crohn's Disease) 01/2021 - 01/2020
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 01/2020
2	Necrosis 01/2022 - 01/2022
1	Infections 01/2022
1	Appendicitis 01/2022
1	Pulmonary Embolism 01/2022
1	Pain (Aches) 01/2021
1	Inflammation (Inflammations) 01/2020
1	Rheumatoid Arthritis 05/2013

Drug/Important Bio-Agent (IBA)

7	etrolizumabIBA 01/2022 - 01/2020
4	IntegrinsIBA 01/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2022
1	Adalimumab (Humira)FDA Link 01/2022
1	Infliximab (Remicade)FDA Link 01/2022
1	Tumor Necrosis Factor InhibitorsIBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	Rituximab (Mabthera)FDA Link 05/2013
1	Antirheumatic Agents (DMARD)IBA 05/2013
1	Biological ProductsIBA 05/2013

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2020
1	Remission Induction 01/2022
1	Injections 01/2021